

**Remarks**

Initially, Applicants acknowledge with appreciation the allowance of claims 1 to 4, 6, 7, 11 to 13, 16, and 19 to 22 of the instant application as provided in the Notice of Allowability mailed on October 16, 2006.

Applicants respectfully request entry of the below-described amendments to claims 2, 3, and 20 and to the specification in connection with the accompanying Request for Continued Examination under 37 C.F.R. 1.114.

The specification has been amended by inserting a Cross-Reference to Related Patent Applications.

Claims 2 and 3 have been amended to place these claims in more acceptable dependent claim format.

Claim 20 has been amended to delete the phrase "or a pharmaceutically acceptable salt thereof" in order to remove any redundancy in said claim.

No new matter has been added by these amendments.

Applicants respectfully submit that, in view of the foregoing amendments and the Information Disclosure Statement filed herewith, the claims remain in condition for allowance.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

  
\_\_\_\_\_  
Kelly L. Bender, Reg. No., 52,610  
Attorney for Applicants

January 12, 2007  
Date  
  
sanofi-aventis  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (610) 889-8995  
Telefax (908) 231-2626  
sanofi-aventis Docket No. IVD000994 US PCT